Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Weighted Average and Diluted) (2020 - 2026)

Kymera Therapeutics (KYMR) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.71 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 13.41% year-over-year to -$0.71; the TTM value through Mar 2026 reached -$3.58, down 15.11%, while the annual FY2025 figure was -$3.69, 23.83% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.71 in Q1 2026 for Kymera Therapeutics, up from -$0.98 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.25 in Q4 2023 and bottomed at -$0.98 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.75, with a median of -$0.78 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) surged 57.63% in 2023 and then crashed 256.0% in 2024.
  • Kymera Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.59 in 2022, then soared by 57.63% to -$0.25 in 2023, then plummeted by 256.0% to -$0.89 in 2024, then decreased by 10.11% to -$0.98 in 2025, then grew by 27.55% to -$0.71 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.71, -$0.98, and -$0.94 for Q1 2026, Q4 2025, and Q3 2025 respectively.